CStone PharmaceuticalsCSPHF -14.46%47 PS Ratio is 22.87 as of Jul. 04, 2026, which is 146% above its 10-year median of 9.31. GuruFocus rates CSPHF with a GF Score™ of 47/100 and a GF Value™ of $0.12 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 933 Biotechnology companies, CStone Pharmaceuticals ranks worse than 69.88% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CStone Pharmaceuticals's share price is $0.5945.
CStone Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03. Hence, CStone Pharmaceuticals's PS Ratio for today is 22.87.
The historical rank and industry rank for CStone Pharmaceuticals's PS Ratio or its related term are showing as below:
CSPHF'
s PS Ratio Range Over the Past 10 Years
Min: 2.11 Med: 9.31 Max: 46.98
Current: 26.18
During the past 10 years, CStone Pharmaceuticals's highest PS Ratio was 46.98. The lowest was 2.11. And the median was 9.31.
CSPHF's PS Ratio is ranked worse than 69.88% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs CSPHF: 26.18
CStone Pharmaceuticals revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of CStone Pharmaceuticals was -37.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -22.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -19.90% per year.
During the past 10 years, CStone Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 10.00% per year. The lowest was -30.10% per year. And the median was -22.30% per year.
Back to Basics: PS Ratio
CStone Pharmaceuticals (OTCPK:CSPHF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CStone Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CStone Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where CStone Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CStone Pharmaceuticals's Share Price of today is $0.5945.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CStone Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
CStone Pharmaceuticals (CSPHF) has a PS Ratio of 22.87 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CStone Pharmaceuticals and its competitors. This is 146% above median its historical median of 9.31. Over the past decade, CStone Pharmaceuticals' PS Ratio has ranged from 2.11 to 46.98. According to the industry distribution chart, CStone Pharmaceuticals ranks #652 out of 933 companies in the Biotechnology industry, placing it in the top 69.9%.
Is CStone Pharmaceuticals' PS Ratio too high?
CStone Pharmaceuticals' current PS Ratio of 22.87 is 146% above median its 10-year median of 9.31. Over the past 10 years, this metric has ranged from a low of 2.11 to a high of 46.98. The Biotechnology industry median PS Ratio is 9.64. CStone Pharmaceuticals' value of 22.87 is 137.2% above this industry median. Based on the distribution chart, CStone Pharmaceuticals ranks #652 out of 933 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CStone Pharmaceuticals has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CStone Pharmaceuticals ranks #652 out of 933 companies for PS Ratio. This places CStone Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 9.64. CStone Pharmaceuticals' value of 22.87 is 137.2% above this benchmark. Historically, CStone Pharmaceuticals' own PS Ratio has ranged from 2.11 to 46.98 over the past decade. While the company's 10-year median is 9.31 vs. the industry median of 9.64, CStone Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CStone Pharmaceuticals's current PS Ratio of 22.87 is 137.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CStone Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CStone Pharmaceuticals's current PS Ratio is 22.87, which is 146% above median its own 10-year median of 9.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (CSPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.12, compared to a current price of $0.59 — trading 395.4% above its estimated fair value. The current PS Ratio is 22.87, which is 146% above median its 10-year median of 9.31 and 137.2% above the Biotechnology industry median of 9.64. CStone Pharmaceuticals' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For CStone Pharmaceuticals (CSPHF), the current PS Ratio is 22.87 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?
Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued.
The current stock price of $0.59 is trading 395.4% above its estimated GF Value™ of $0.12.
GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CSPHF:
PS Ratio: 22.87 (146% above median its 10-year median of 9.31)
GF Value™: $0.12 vs. price of $0.59 (395.4% above fair value)
Industry Position: 137.2% above the Biotechnology median (#652 of 933)
No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
47GF Score
Get the complete analysis for CSPHF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPHF has been successfully added to your 
